Tareg Dosage/Direction for Use





Zuellig Pharma
Full Prescribing Info
Dosage/Direction for Use
Hypertension: Recommended Dose: 80 or 160 mg once daily, irrespective of race, age or gender. The antihypertensive effect is substantially present within 2 weeks and maximal effects are seen after 4 weeks. In patients whose blood pressure is not adequately controlled, the daily dose may be increased to 320 mg or a diuretic may be added.
Renal Impairment/Hepatic Insufficiency: No dosage adjustment is required for patients with renal impairment or for patients with hepatic insufficiency of nonbiliary origin and without cholestasis.
Tareg may also be administered with other antihypertensive agents.
Heart Failure: Recommended Starting Dose: 40 mg twice daily. Uptitration to 80 and 160 mg twice daily should be done to the highest dose, as tolerated by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose administered in clinical trials is 320 mg in divided dose.
Evaluation of patients with heart failure should always include assessment of renal function.
Post-Myocardial Infarction: Therapy may be initiated as early as 12 hrs after a myocardial infarction. After an initial dose of 20 mg twice daily, valsartan therapy should be titrated to 40, 80 and 160 mg twice daily over the next few weeks. The starting dose is provided by the 40-mg divisible tablet. Achievement of the target dose of 160 mg twice daily should be based on the patient's tolerability to valsartan during titration. If symptomatic hypotension or renal dysfunction occur, consideration should be given to a dosage reduction.
Valsartan may be used in patients treated with other post-myocardial infarction therapies eg, thrombolytics, acetylsalicylic acid, β-blockers and statins.
Children: The safety and efficacy of Tareg have not been established in children.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in